213,285 Orion Corporation A-shares converted into B-shares

ORION COMPANY
STOCK EXCHANGE REPORT – OTHER INFORMATION MADE PUBLIC IN ACCORDANCE WITH STOCK EXCHANGE RULES
SEPTEMBER 20, 2024 at 9:30 EEST

213,285 Orion Corporation A-shares converted into B-shares

In accordance with Article 3 of the Articles of Association of Orion Corporation, 213,285 A-shares have been converted into 213,285 B-shares. The conversion has been entered in the Trade Register on 20 September 2024.

The total number of shares in Orion Corporation is 141,134,278, which after the conversion consists of 32,974,309 A shares and 108,159,969 B shares. The number of voting rights of the company’s shares after the conversion is 767,646,149.

Orion Corporation

Contact person:
Tuukka Hirvonen, Investor Relations, tel. +358 10 426 2721

Publisher:
Orion Corporation
Communication
Orionintie 1A, FI-02200 Espoo, Finland
http://www.orion.fi/en
http://www.twitter.com/OrionCorpIR

Orion is a global Finnish pharmaceutical company – a builder of well-being for over a hundred years. We develop, manufacture and market human and veterinary pharmaceutical products and active pharmaceutical ingredients. Orion has an extensive portfolio of patented and generic pharmaceuticals and consumer health products. The core therapy areas of our pharmaceutical R&D are oncology and pain. The patented products developed by Orion are used, among others, to treat cancer, neurological disorders and respiratory diseases. Orion’s net sales in 2023 amounted to EUR 1,190 million and the company had approximately 3,600 employees at the end of the year. Orion’s A and B shares are listed on Nasdaq Helsinki.